Le Lézard
Classified in: Health
Subjects: TRI, FDA

Visibly Becomes First FDA-Cleared Online Vision Test in the United States


CHICAGO, August 16, 2022 /PRNewswire/ -- Visibly, the developer of the world's first at-home digital vision testing platform, is excited to announce that, as of August 12, 2022, it has received 510(k) Clearance from the United States Food and Drug Administration for its Visibly Digital Acuity Product (VDAP). Visibly becomes the first FDA-cleared online visual acuity test on the US market.

Visibly is excited to announce that it has received 510(k) Clearance from the United States Food and Drug Administration!

With their newly-acquired 510(k) Clearance from the FDA, Visibly's telemedicine platform can continue to expand affordable access to vision care for millions of consumers. Consumers can access Visibly's on-demand, self-administered visual acuity test using a combination of a touchscreen mobile device and computer connected to the internet. Consumers can take the test at any time and complete the entire experience in about 6 minutes. Completed vision test results are made available to Eye Care Professionals immediately and securely, helping them evaluate the best course of action for each patient.

"After many years working with the FDA, we are excited to receive this clearance ...", says Brent Rasmussen, CEO of Visibly. "...We look forward to fulfilling our mission of bringing affordable, accessible vision care to the masses."

Visibly will continue to offer a convenient, affordable way to assess vision at home.

Paul Foley, Visibly's COO, commented, "We are thrilled to achieve this milestone. Our Performance Data, including our prospective, multi-center clinical study that evaluated the safety and effectiveness of VDAP compared to an ETDRS Visual Acuity Lane Test, demonstrated that the safety and effectiveness of VDAP are substantially equivalent to those of its predicate device. VDAP's clinical performance will aid Eye Care Professionals in the remote evaluation of visual acuity and connect patients with care in a way that was not available before."

Visibly is eager to accelerate its mission to partner with the leading optical organizations to equip Eye Care Professionals and their patients with a convenient and affordable way to get information about how well people are seeing from their own homes.

About Visibly

Visibly is a Chicago-based healthcare technology company founded in 2012, building digital vision care solutions that enable patient choice and provider capacity. Online vision testing is just the start; Visibly envisions a world where technology enables patients and doctors to connect easily and make other aspects of vision care more convenient and accessible to everyone.

SOURCE Visibly


These press releases may also interest you

at 10:05
Pharmaceutical Strategies Group ("PSG"), an EPIC company, has added two significant enhancements to its leadership team aimed at further empowering healthcare payers and driving innovation within the pharmacy benefits industry. The company welcomes...

at 10:05
OverT Bio, a data-driven company working to unlock the curative potential of cell therapies in solid tumors, announced today that it has raised $16 million in seed funding. The round was co-led by ARTIS Ventures and Wing VC, with participation from...

at 10:05
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing...

at 10:05
BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, unveils today a selection of leading research centers collaborations. For its partners, BrainTale offers innovative...

at 10:00
Amid the rapid advancement in automobile healthcare and digital healthcare markets, global car manufacturers are racing to adopt cutting edge healthcare technologies for in-vehicle driver health monitoring....

at 10:00
Endovascular Engineering, Inc. ("E2"), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), proudly announced positive safety and feasibility results from its ENGULF US clinical...



News published on and distributed by: